Management Team

Nightingale’s CEO is appointed by the Board of Directors. The CEO manages and develops Nightingale’s business and is in charge of the operative administration of Nightingale in accordance with the instructions of the Board of Directors. The CEO presents matters and reports to the Board of Directors. The CEO ensures that the company’s accounting complies with legislation and that the management of the company’s assets is organised in a reliable manner.

Nightingale’s Management Team reports to the CEO and supports and assists the CEO in the efficient management of the company’s operations.

Nightingale's Management Team

Teemu Suna

Chief Executive Officer, Founder
Born 1982
Finnish citizen
M.Sc. (Tech)
CEO and Management Team member since 2014
Main work experience: Fujitsu Services Oy, Chief Technology Officer, 2011–2014; Fujitsu Services Oy, Principal Solutions Architect, 2007–2011; Ramse Consulting Oy, ICT Consultant, 2006–2007; Aalto yliopisto, ICT and Advanced Data Analysis Researcher, 2005–2006; Brainshake Oy, Director and Co-Founder, 2002–2005
Holdings in the company: 2,637,964 Series A shares, 22,737 Series B shares, 2,000,000 Series B options, entitling to same amount of shares in the company with the right to subscribe in case defined market value is reached

Antti Kangas

Chief Technology Officer, Founder
Born 1984
Finnish citizen
M.Sc. (Tech)
Management Team member since 2014
Main work experience: University of Oulu, Researcher, 2008–2015; Helsinki University of Technology, Research Assistant, 2006–2008; Innofactor Oyj, Software Developer, 2004–2006; Freelance Software Developer, Graphics Designer and Information Visualisation Consultant, 1998–2003
Holdings in the company: 5,340,342 Series A shares, 17,458 Series B shares, 0 options

Satu Saksman

Chief Operating Officer, Co-founder
Born 1976
Finnish citizen
M.Sc. (Tech)
Management Team member since 2015
Main work experience: Neste Jacobs Oy, Sales Manager, 2015–2016; Independent business development consultant, 2012–2015, Neroko Oy; Chief Executive Officer and Co-partner, 2010–2013; Linde Group / Oy AGA Ab, Key Account Manager, 2005–2010; Metso Panelboard Oy, Team and Product Manager, 2002–2005
Holdings in the company: 529,158 Series A shares, 17,458 Series B shares, 75,250 EMP shares, 1,000,000 Series B options with the right to subscribe in case defined market value is reached and 1,550 EMP options, each entitling to 301 shares in the company

Minja Salmio

Chief Legal Officer
Born 1987
Finnish citizen
LL.M.
Management Team member since 2017
Main work experience: Attorneys at Law Merilampi Ltd Oy, Senior Associate and Associate, 2013–2017; District Court of Länsi-Uusimaa, Judge Trainee, 2012; Attorneys at Law Ratiolex Ltd, Associate, 2011
Holdings in the company: 82,775 EMP shares, 1,000,000 Series B options with the right to subscribe in case defined market value is reached and 1,550 EMP options, each entitling to 301 shares in the company

Tuukka Paavola

Chief Financial Officer
Born 1980
Finnish citizen
M.Sc. (Tech), CFA
Management Team member since 2021
Main work experience: Nordea Bank Abp: First Vice President, Group Strategy, 2020–2021; Head of CEO Office, 2019–2020; Head of Wholesale Banking Operations Change, 2016–2019; Management Partner, CFO Office, 2013–2016; Senior Analyst, Nordea Markets, 2010–2013
Holdings in the company: 0 shares, 0 options

Salla Ruosaari

Chief R&D Officer
Born 1976
Finnish citizen
PhD
Management Team member since 2021
Main work experience: Nightingale Health Oy, Business Director, 2017–2021; Icare Finland Oy, Business Manager / Commercial Product Manager, 2016–2017; Biohit Oyj, Key Account Manager, 2015–2016; Labquality Oy, Key Account Manager, 2013–2015; Thermo Fisher Scientific Oy, Marketing and Product Manager, 2010–2013; PerkinElmer Finland Oy, Business and Product Manager, 2008–2010
Holdings in the company: 75,250 EMP shares and 250 EMP options, each entitling to 301 shares in the company

Jeffrey Barrett

Chief Scientific Officer
Born 1980
American and Irish citizen
PhD, FMedSci
Management Team member since 2021
Main work experience: Wellcome Sanger Institute, Director of SARS-CoV-2 Genomics Initiative, 2020–2021; Genomics plc, Chief Scientific Officer & Director, 2018–2020; Open Targets, Director, 2015–2018; Wellcome Sanger Institute, Group Leader, Senior Group Leader, 2008–2018; University of Cambridge, Postdoc, 2008; Whitehead Institute for Biomedical Research, Analyst / Software developer, 2002–2005
Holdings in the company: 0 shares, 0 options

For individuals

For business

Nightingale for business

Health initiatives

For investors

Investor pages

Nightingale as an investment

Financial information